Zamora, C.; Diaz-Torne, C.; Ortiz, M.A.; Moya, P.; Park, H.S.; Pitarch, C.; Cantó, E.; Osuna-Gomez, R.; Mulet, M.; Garcia-Arguinzonis, M.;
et al. Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells 2025, 14, 625.
https://doi.org/10.3390/cells14090625
AMA Style
Zamora C, Diaz-Torne C, Ortiz MA, Moya P, Park HS, Pitarch C, Cantó E, Osuna-Gomez R, Mulet M, Garcia-Arguinzonis M,
et al. Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells. 2025; 14(9):625.
https://doi.org/10.3390/cells14090625
Chicago/Turabian Style
Zamora, Carlos, Cesar Diaz-Torne, Maria Angels Ortiz, Patricia Moya, Hye Sang Park, Concepció Pitarch, Elisabet Cantó, Ruben Osuna-Gomez, Maria Mulet, Maisa Garcia-Arguinzonis,
and et al. 2025. "Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis" Cells 14, no. 9: 625.
https://doi.org/10.3390/cells14090625
APA Style
Zamora, C., Diaz-Torne, C., Ortiz, M. A., Moya, P., Park, H. S., Pitarch, C., Cantó, E., Osuna-Gomez, R., Mulet, M., Garcia-Arguinzonis, M., Collado, D., Corominas, H., & Vidal, S.
(2025). Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells, 14(9), 625.
https://doi.org/10.3390/cells14090625